Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Amgen still head of class in CGRP-migraine

Mary Romeo, Assistant Editor
July 31, 2019 12:44 AM UTC

As Amgen and Lilly continue to expand their presence in the migraine prevention market, the former's first-in-class CGRP inhibitor is maintaining its lead in the space.

Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Co. (NYSE:LLY) reported 2Q19 sales of their calcitonin-related gene peptide (CGRP) inhibitors to treat migraine Tuesday. Aimovig erenumab-aooe generated $83 million in sales for the quarter, up 41% from 1Q19 and beating analyst expectations of $75.2 million...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Eli Lilly and Co.

Teva Pharmaceutical Industries Ltd.